TrialJournal for immunotherapy of cancer2019

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM

M Fishman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.